• Magazine
    • Current Issue
    • Past Issues
    • Subscribe
    • Change Mailing Address
    • Surveys
    • Guidelines for Authors
    • Editorial Calendar and Deadlines
    • Dynamic Chiropractic
      • Newspaper
      • Subscription
    • The American Chiropractor
      • Magazine
  • Practice
    • Business Tips
    • Chiropractic Schools
    • Clinical & Technique
    • Ebooks
    • Ecourses
    • Sponsored Content
    • Infographics
    • Quizzes
    • Wellness & Nutrition
    • Podcast
  • Content Hubs
  • Products & Services
    • View Products & Services Directory
    • Browse Buyers Guide
    • Submit a Product
    • Vendor Login
  • Datebook
    • View Events
    • Post an Event
    • Become an Events Poster
  • Advertise
    • Advertising Information
    • Media Kit
    • Contact Us

Your Online Practice Partner

Chiropractic Economics
Your Online Practice Partner
Advertise Subscribe
  • Home
  • News
  • Webinars
  • Chiropractic Research
  • Students/New DCs

Theralase commences small animal pre-clinical trials for destruction of cancer cells

Chiropractic Economics November 13, 2010

November 13, 2010 — Theralase Technologies Inc. (TSX-V: TLT) has commenced the pre-clinical trial phase of its cancer research project; evaluating its patented Photo Dynamic Compounds (PDCs) in a small animal in-vivo model.

Lothar Lilge, PhD, the principal investigator of the PDCs and a researcher at the world renowned Ontario Cancer Institute located at Princess Margaret Hospital, University Health Network (UHN) will evaluate the toxicity of the patented PDCs on small animals, by choosing an escalating dose analysis.

Once completed, Lilge plans to demonstrate efficacy of the PDCs in the destruction of tumours in a small animal model.

Theralase first announced commencing small animal trials in June 2010. Testing can now proceed following receipt of approvals on its Animal Utilization Protocol by the UHN Ethics Review Committee.

“These small animal pre-clinical trials represent the next strategic step forward in our cancer therapy research program”, says Theralase President and CEO, Roger Dumoulin-White. “Now that approval has been granted, hands-on evaluation of the PDCs in a small animal model is able to commence full steam ahead. Successful completion of this milestone, will lay the groundwork for exploring the use of these PDCs in the destruction of cancers in larger animals, including: horses, cats, dogs and eventually humans.”

Lilge stated that, “Determination of the maximum tolerated dose is critical to providing us with safe PDC dosage levels that we can use to set recommended dosing guidelines to evaluate the efficacy of the PDCs in eradicating tumours in small animals while sparing normal tissue. Successfully destroying cancer in at least 2 animal models coupled with the completion of an OECD guideline toxicology analysis of the PDCs will be mandatory in setting the stage for future Phase 1 human clinical trials. We are currently investigating toxicity of four lead compounds in the safe and effective destruction of cancer cells in vivo. Due to the ability of these PDCs to work in low oxygen environments, these PDCs will be ideally suited in the destruction of solid core tumours, such as cancers of the breast, prostate, brain and lung.”

Source: Theralase, www.theralase.com

 

Related Posts

  • American Chiropractic Association elects new president, VPAmerican Chiropractic Association elects new president, VP
  • League of Chiropractic Women to host Women’s Success Summit in NovemberLeague of Chiropractic Women to host Women’s Success Summit in November
  • Adding specialty services to your chiropractic practiceAdding specialty services to your chiropractic practice
  • Palmer College of Chiropractic community mourns John MillerPalmer College of Chiropractic community mourns John Miller
  • The vital role of vitamin B-12: Essential things every DC should know about B-12 deficiencyThe vital role of vitamin B-12: Essential things every DC should know about B-12 deficiency

Filed Under: Industry News, News

Current Issue

Issue 7 cover

Get Exclusive Content! Join our email list

Follow Us

  • Facebook
  • X (Twitter)
  • Instagram
  • LinkedIn
  • YouTube logoYouTube logoYouTube

Compare Subscriptions

Dynamic Chiropractic

The American Chiropractor

8430 Enterprise Circle, Suite 200

Lakewood Ranch, FL 34202

Phone 800-671-9966

CONTACT US »

Privacy Policy | Terms of Service

Copyright © Chiropractic Economics, A Gallagher Company. All Rights Reserved.

SUBSCRIBE TO THE MAGAZINE

Get Chiropractic Economics magazine
delivered to your home or office. Just
fill out our form to request your FREE
subscription for 20 issues a year,
including two annual Buyers Guides.

SUBSCRIBE NOW »